参考文献/References:
[1]Ward RD,Tanaka H,Campbell SC,et al.2017 AUA Renal Mass and Localized Renal Cancer Guidelines[J],Imaging Implications Radiographics,2018,38(7):2021-2033.[2]Cui H,Shan H,Miao MZ,et al.Identification of the key genes and pathways involved in the tumorigenesis and prognosis of kidney renal clear cell carcinoma[J].Sci Rep,2020,10(1):4271. [3]Moch H,Montironi R,Lopez-Beltran A,et al.Oncotargets in different renal cancer subtypes[J].Curr Drug Targets,2015,16(2):125-135. [4]Valera VA,Merino MJ.Misdiagnosis of clear cell renal cell carcinoma[J].Nat Rev Urol,2011,8(6):321-333. [5]Ran L,Liang J,Deng X,et al.miRNAs in Prediction of Prognosis in Clear Cell Renal Cell Carcinoma[J].Biomed Res Int,2017,2017:4832931. [6]Li QK,Pavlovich CP,Zhang H,et al.Challenges and opportunities in the proteomic characterization of clear cell renal cell carcinoma (ccRCC): A critical step towards the personalized care of renal cancers[J].Semin Cancer Biol,2019,55:8-15. [7]Yang H,Song E,Shen G,et al.Expression of microRNA-30c via lentivirus vector inhibits the proliferation and enhances the sensitivity of highly aggressive ccRCC Caki-1 cells to anticancer agents[J].Onco Targets Ther,2017,10:579-590. [8]Khadirnaikar S,Kumar P,Pandi SN,et al.Immune associated LncRNAs identify novel prognostic subtypes of renal clear cell carcinoma[J].Mol Carcinog,2019,58(4):544-553. [9]Zhang Y,Wang J,Liu X.LRRC19-A Bridge between Selenium Adjuvant Therapy and Renal Clear Cell Carcinoma: A Study Based on Datamining[J].Genes (Basel),2020,11(4):440. [10]Liu W,Cai T,Li L,et al.MiR-200a Regulates Nasopharyngeal Carcinoma Cell Migration and Invasion by Targeting MYH10[J].J Cancer,2020,11(10):3052-3060.[11]Glück U,Kwiatkowski DJ,Ben-Ze’ev A.Suppression of tumorigenicity in simian virus 40-transformed 3T3 cells transfected with alpha-actinin cDNA[J].Bioassays,1993,90(2):383-387.[12]Fernández JLR,Geiger B,Salmon D,et al.Suppression of tumorigenicity in transformed cells after transfection with vinculin cDNA[J].Cell Biol,1992,119:427-438.[13]Boyd J,Risinger JI,Wiseman RW,et al.Regulation of microfilament organization and anchorage-independent growth by tropomyosin 1[J].Proc Natl Acad Sci USA,1995,92(25):11534-11538.[14]Gimona M,Kazzaz JA,Helfman DM.Forced expression of tropomyosin 2 or 3 in v-Ki-ras-transformed fibroblasts results in distinct phenotypic effects[J].Proc Natl Acad Sci U S A,1996,93(18):9618-9623.[15]Mahnken AH,Thomson K,deHaan M,et al.CIRSE standards of practice guidelines on iliocaval stenting[J].CardiovascIntervent Radiol,2014,37(4):889-897.[16]Pellerin O,Baudin G,di Primio M,et al.Endovascular treatment for post-thrombotic syndrome. Two case studies and a literature review[J].Diagn Interv Imaging,2012,93(5):380-385.[17]Rhodes DR,Yu J,Shanker K,et al.ONCOMINE: a cancer microarray database and integrated data-mining platform[J].Neoplasia,2004,6:1-6.[18]Neglén P,Raju S.Balloon dilation and stenting of chronic iliac vein obstruction:technical aspects and early clinical outcome[J].Journal Of Endovascular Therapy,2000,7(2):79-91.[19]Jiao M,Guo H,Chen Y,et al.DARS-AS1 promotes clear cell renal cell carcinoma by sequestering miR-194-5p to up-regulate DARS[J].Biomed Pharmacother,2020,128:110323. [20]Yuan C,Xiong Z,Shi J,et al.Overexpression of PPT2 Represses the Clear Cell Renal Cell Carcinoma Progression by Reducing Epithelial-to-mesenchymal Transition[J].J Cancer,2020,11(5):1151-1161.[21]Reyes A,He J,Mao CC,et al.Actin and myosin contribute to mammalian mitochondrial DNA maintenance[J].Nucleic Acids Res,2011,39(12):5098-5108.[22]成重峰,徐婷,荆涛,等.A1AT、MYH10在膀胱尿路上皮癌中的表达及其临床意义[J].现代泌尿外科杂志,2015(6):395-398.[23]刘龙阳.MYH10诱导MYH9促进卵巢癌增殖、迁移侵袭的研究[D].广州:南方医科大学,2019.[24]Wang Y,Yang Q,Cheng Y,et al.Myosin Heavy Chain 10 (MYH10) Gene Silencing Reduces Cell Migration and Invasion in the Glioma Cell Lines U251, T98G, and SHG44 by Inhibiting the Wnt/β-Catenin Pathway[J].Med Sci Monit,2018(24):9110-9119.[25]李凯迪,王海,郑岩,等.MYH10在结直肠癌中的表达及意义[J].中国实验诊断学,2020(5):800-803.
相似文献/References:
[1]毛 伟,张 琳,刘清钊.肾透明细胞癌细胞焦亡相关基因预后模型的建立与应用[J].医学信息,2022,35(14):1.[doi:10.3969/j.issn.1006-1959.2022.14.001]
MAO Wei,ZHANG Lin,LIU Qing-zhao.Constructionand Application of Pyroptosis-related Genes Prognosis Model in Clear Cell Renal Cell Carcinoma[J].Medical Information,2022,35(10):1.[doi:10.3969/j.issn.1006-1959.2022.14.001]
[2]李 松,李瑞杰,赵小磊.CDKN2A基因突变与肾细胞癌药物敏感性和预后的关系[J].医学信息,2022,35(16):1.[doi:10.3969/j.issn.1006-1959.2022.16.001]
LI Song,LI Rui-jie,ZHAO Xiao-lei.Relationship Between CDKN2A Gene Mutation and Drug Sensitivity and Prognosis of Renal Cell Carcinoma[J].Medical Information,2022,35(10):1.[doi:10.3969/j.issn.1006-1959.2022.16.001]
[3]李前进,拜合提亚·阿扎提,王文光,等.ST6GalⅠ在肾透明细胞癌中表达及其与病理特征的关系[J].医学信息,2021,34(06):87.[doi:10.3969/j.issn.1006-1959.2021.06.022]
LI Qian-jin,Baihetia Azati,WANG Wen-guang,et al.The Expression of ST6GalⅠ in Renal Clear Cell Carcinoma and Its Relationship with Pathological Features[J].Medical Information,2021,34(10):87.[doi:10.3969/j.issn.1006-1959.2021.06.022]
[4]吴文杰,裴天龙,汪永康,等.基于CT影像组学特征预测肾透明细胞癌分化程度的研究[J].医学信息,2021,34(11):96.[doi:10.3969/j.issn.1006-1959.2021.11.026]
WU Wen-jie,PEI Tian-long,WANG Yong-kang,et al.Study on Predicting Differentiation Degree of Renal Clear Cell Carcinoma Based on CT Imaging Features[J].Medical Information,2021,34(10):96.[doi:10.3969/j.issn.1006-1959.2021.11.026]
[5]单 丽,朱晓力,向程程,等.基于NUF2mRNA、HAMP mRNA、分期、病理分级及年龄的预后评估模型在肾透明细胞癌预后判断中的运用[J].医学信息,2023,36(09):42.[doi:10.3969/j.issn.1006-1959.2023.09.007]
SHAN Li,ZHU Xiao-li,XIANG Cheng-cheng,et al.The Application of Prognostic Evaluation Model Based on NUF2mRNA,HAMP mRNA,Stage,Pathological Grade and Age in the Prognosis of Kidney Renal Clear Cell Carcinoma[J].Medical Information,2023,36(10):42.[doi:10.3969/j.issn.1006-1959.2023.09.007]